@article{dd155ac633bf4cfd95de184b124860d0,
title = "The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii",
abstract = "The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.",
author = "Lockhart, {Shawn R.} and Bodi, {Annette M} and Naureen Iqbal and Bolden, {Carol B.} and Grossman, {Nina T.} and Garvey, {Edward P.} and Brand, {Stephen R.} and Hoekstra, {William J.} and Schotzinger, {Robert J.} and Elizabeth Ottinger and Patterson, {Thomas F.} and Wiederhold, {Nathan P.}",
note = "Funding Information: This project was funded by the National Institutes of Health National Institute of Allergy and Infectious Diseases under contract no. N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was provided by Viamet Pharmaceuticals, Inc. Publisher Copyright: Copyright {\textcopyright} 2016, American Society for Microbiology. All Rights Reserved.",
year = "2016",
month = apr,
doi = "10.1128/AAC.02770-15",
language = "English (US)",
volume = "60",
pages = "2528--2531",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",
}